T Cell Exhaustion Could Be Regulating by Yangyin Fuzheng Decoction in Lewis Lung Cancer in a Tumor Burdened Mice

2020 ◽  
Vol 10 (02) ◽  
pp. 31-40
Author(s):  
梅 姜
2019 ◽  
Author(s):  
Caroline Laheurte ◽  
Magalie Dosset ◽  
Dewi Vernerey ◽  
Elodie Lauret Marie Joseph ◽  
Laura Boullerot ◽  
...  

2015 ◽  
Vol 195 (2) ◽  
pp. 541-549 ◽  
Author(s):  
Rohit Mittal ◽  
Ching-Wen Chen ◽  
John D. Lyons ◽  
Lindsay M. Margoles ◽  
Zhe Liang ◽  
...  

2021 ◽  
Author(s):  
James L. Reading ◽  
Rachel Rosenthal ◽  
Lucas Black ◽  
Seng Kuong Ung ◽  
Claire Streatfield ◽  
...  

2019 ◽  
Author(s):  
Caroline Laheurte ◽  
Magalie Dosset ◽  
Dewi Vernerey ◽  
Elodie Lauret Marie Joseph ◽  
Laura Boullerot ◽  
...  

2016 ◽  
Vol 186 (1) ◽  
pp. 106-114 ◽  
Author(s):  
C. Y. Hu ◽  
Y. H. Zhang ◽  
T. Wang ◽  
L. Chen ◽  
Z. H. Gong ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Yinnan Meng ◽  
Wei Wang ◽  
Meng Chen ◽  
Kuifei Chen ◽  
Xinhang Xia ◽  
...  

IDO1-mediated immune escape can lead to the malignant progression of tumors. However, the precise mechanism of IDO1 remains unclear. This study showed that IDO1 can bind to GBP1 and increase the extracellular secretion of IDO1 with the assistance of GBP1, thereby promoting the malignant proliferation and metastasis of lung cancer. In vitro study showed that the high expression levels of IDO1 and GBP1 in lung cancer cells promoted cell invasion and migration. In vivo study revealed that knock-down of IDO1 and GBP1 inhibited tumor growth and metastasis. In addition, Astragaloside IV reduces the extracellular secretion of IDO1 by blocking the interaction of IDO1 and GBP1, thereby reducing T cell exhaustion and inhibiting tumor progression. These results suggest that blocking the extracellular secretion of IDO1 may prevent T cell exhaustion and thereby enhance the effect of PD-1 inhibitors on cancer treatment.


2018 ◽  
Vol 46 (04) ◽  
pp. 911-922 ◽  
Author(s):  
Huiying Fu ◽  
Lu Jin ◽  
Xia Shao ◽  
Yuanyuan Li ◽  
Fangming Chen ◽  
...  

Hirsutella sinensis fungus (HSF) is an artificial substitute of the well-known medicine Cordyceps sinensis with similar beneficial effects in humans. We previously found that HSF can regulate immune function and inhibit tumor growth; however, the mechanisms involved in these effects were still unclear. Accordingly, in this study, we investigated the effects of HSF on immune cell subsets in the tumor microenvironment in mice. The results showed that HSF inhibited Lewis lung cancer growth, alleviated abnormalities in routine blood tests, and enhanced tumor-infiltrating T cells, particularly the proportion of effector CD8[Formula: see text] T cells. In addition, HSF also ameliorated the immune-suppressive microenvironment and decreased the proportions of regulatory T cell and myeloid-derived suppressor cell populations. To confirm the effects of HSF on promotion of effector CD8[Formula: see text] T-cell production, we further evaluated changes in postoperative metastasis following treatment with HSF. Indeed, orthotopic lung metastasis was significantly suppressed, and survival times were increased in HSF-treated mice. Taken together, our findings suggested that HSF inhibited Lewis lung cancer by enhancing the population of effective CD8[Formula: see text] T cells.


Sign in / Sign up

Export Citation Format

Share Document